{"id":44030,"date":"2025-10-21T21:29:13","date_gmt":"2025-10-21T13:29:13","guid":{"rendered":"https:\/\/flcube.com\/?p=44030"},"modified":"2025-10-21T21:29:14","modified_gmt":"2025-10-21T13:29:14","slug":"sichuan-biokin-launches-phase-iii-trial-of-t%e2%80%91bren-for-her2%e2%80%91mutant-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44030","title":{"rendered":"Sichuan Biokin Launches Phase\u202fIII Trial of T\u2011Bren for HER2\u2011Mutant NSCLC"},"content":{"rendered":"\n<p><strong>Sichuan Biokin Pharmaceutical Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>)<\/strong> announced today the enrollment of the first patient in its Phase\u202fIII clinical trial of <strong>T\u2011Bren for Injection (HER2 ADC)<\/strong> versus <strong>pembrolizumab plus platinum\u2011based chemotherapy<\/strong> for first\u2011line treatment of <strong>advanced or metastatic non\u2011squamous non\u2011small cell lung cancer (NSCLC) with HER2 mutations<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-trial-highlights\"><strong>Key Trial Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011class HER2\u2011targeting antibody\u2011drug conjugate (ADC)<\/strong> \u2013 T\u2011Bren (BL\u2011M07D1) has shown <strong>significant antitumor efficacy<\/strong> in early\u2011phase studies.<\/li>\n\n\n\n<li><strong>Phase\u202fIII design<\/strong> \u2013 Randomized, open\u2011label, multi\u2011center study comparing T\u2011Bren to the current standard of care (pembrolizumab\u202f+\u202fplatinum).<\/li>\n\n\n\n<li><strong>Patient enrollment milestone<\/strong> \u2013 First patient screened and dosed on the study site, marking the official start of the Phase\u202fIII program.<\/li>\n\n\n\n<li><strong>Strategic positioning<\/strong> \u2013 The trial targets the growing market of HER2\u2011mutant NSCLC, a subset with limited therapeutic options and poor prognosis.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-t-bren-bl-m07d1\"><strong>About T\u2011Bren (BL\u2011M07D1)<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovative HER2\u2011ADC platform<\/strong> \u2013 Combines a humanized HER2\u2011specific antibody with a potent cytotoxic payload, delivering targeted cell\u2011killing while sparing normal tissue.<\/li>\n\n\n\n<li><strong>Preclinical\/early\u2011phase data<\/strong> \u2013 Demonstrated robust tumor regression in HER2\u2011positive models and favorable safety profile.<\/li>\n\n\n\n<li><strong>Competitive advantage<\/strong> \u2013 First ADC to specifically target HER2 mutations in NSCLC, potentially offering superior efficacy over existing checkpoint\u2011based therapies.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-impact-for-sichuan-biokin\"><strong>Strategic Impact for Sichuan Biokin<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated development pipeline<\/strong> \u2013 Successful Phase\u202fIII initiation positions T\u2011Bren for regulatory submission in China, the U.S., and other key markets.<\/li>\n\n\n\n<li><strong>Market differentiation<\/strong> \u2013 By addressing an underserved patient population, the company can capture significant market share in the rapidly expanding HER2\u2011oncology segment.<\/li>\n\n\n\n<li><strong>Future roadmap<\/strong> \u2013 Positive results could pave the way for T\u2011Bren\u2019s expansion into other HER2\u2011driven malignancies (e.g., breast, gastric) and combination strategies.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today the enrollment of the first patient&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44031,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,151,16,62,857],"class_list":["post-44030","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-cancer","tag-clinical-trial-approval-initiation","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sichuan Biokin Launches Phase\u202fIII Trial of T\u2011Bren for HER2\u2011Mutant NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today the enrollment of the first patient in its Phase\u202fIII clinical trial of T\u2011Bren for Injection (HER2 ADC) versus pembrolizumab plus platinum\u2011based chemotherapy for first\u2011line treatment of advanced or metastatic non\u2011squamous non\u2011small cell lung cancer (NSCLC) with HER2 mutations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44030\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin Launches Phase\u202fIII Trial of T\u2011Bren for HER2\u2011Mutant NSCLC\" \/>\n<meta property=\"og:description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today the enrollment of the first patient in its Phase\u202fIII clinical trial of T\u2011Bren for Injection (HER2 ADC) versus pembrolizumab plus platinum\u2011based chemotherapy for first\u2011line treatment of advanced or metastatic non\u2011squamous non\u2011small cell lung cancer (NSCLC) with HER2 mutations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44030\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T13:29:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-21T13:29:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2110.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44030#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44030\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin Launches Phase\u202fIII Trial of T\u2011Bren for HER2\u2011Mutant NSCLC\",\"datePublished\":\"2025-10-21T13:29:13+00:00\",\"dateModified\":\"2025-10-21T13:29:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44030\"},\"wordCount\":315,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44030#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2110.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44030#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44030\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44030\",\"name\":\"Sichuan Biokin Launches Phase\u202fIII Trial of T\u2011Bren for HER2\u2011Mutant NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44030#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44030#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2110.webp\",\"datePublished\":\"2025-10-21T13:29:13+00:00\",\"dateModified\":\"2025-10-21T13:29:14+00:00\",\"description\":\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today the enrollment of the first patient in its Phase\u202fIII clinical trial of T\u2011Bren for Injection (HER2 ADC) versus pembrolizumab plus platinum\u2011based chemotherapy for first\u2011line treatment of advanced or metastatic non\u2011squamous non\u2011small cell lung cancer (NSCLC) with HER2 mutations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44030#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44030\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44030#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2110.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2110.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sichuan Biokin Launches Phase\u202fIII Trial of T\u2011Bren for HER2\u2011Mutant NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44030#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin Launches Phase\u202fIII Trial of T\u2011Bren for HER2\u2011Mutant NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin Launches Phase\u202fIII Trial of T\u2011Bren for HER2\u2011Mutant NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today the enrollment of the first patient in its Phase\u202fIII clinical trial of T\u2011Bren for Injection (HER2 ADC) versus pembrolizumab plus platinum\u2011based chemotherapy for first\u2011line treatment of advanced or metastatic non\u2011squamous non\u2011small cell lung cancer (NSCLC) with HER2 mutations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44030","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin Launches Phase\u202fIII Trial of T\u2011Bren for HER2\u2011Mutant NSCLC","og_description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today the enrollment of the first patient in its Phase\u202fIII clinical trial of T\u2011Bren for Injection (HER2 ADC) versus pembrolizumab plus platinum\u2011based chemotherapy for first\u2011line treatment of advanced or metastatic non\u2011squamous non\u2011small cell lung cancer (NSCLC) with HER2 mutations.","og_url":"https:\/\/flcube.com\/?p=44030","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-21T13:29:13+00:00","article_modified_time":"2025-10-21T13:29:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2110.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44030#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44030"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin Launches Phase\u202fIII Trial of T\u2011Bren for HER2\u2011Mutant NSCLC","datePublished":"2025-10-21T13:29:13+00:00","dateModified":"2025-10-21T13:29:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44030"},"wordCount":315,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44030#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2110.webp","keywords":["ADC \/ XDC","Biokin Pharmaceutical","Cancer","Clinical trial approval \/ initiation","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44030#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44030","url":"https:\/\/flcube.com\/?p=44030","name":"Sichuan Biokin Launches Phase\u202fIII Trial of T\u2011Bren for HER2\u2011Mutant NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44030#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44030#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2110.webp","datePublished":"2025-10-21T13:29:13+00:00","dateModified":"2025-10-21T13:29:14+00:00","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today the enrollment of the first patient in its Phase\u202fIII clinical trial of T\u2011Bren for Injection (HER2 ADC) versus pembrolizumab plus platinum\u2011based chemotherapy for first\u2011line treatment of advanced or metastatic non\u2011squamous non\u2011small cell lung cancer (NSCLC) with HER2 mutations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44030#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44030"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44030#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2110.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2110.webp","width":1080,"height":608,"caption":"Sichuan Biokin Launches Phase\u202fIII Trial of T\u2011Bren for HER2\u2011Mutant NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44030#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin Launches Phase\u202fIII Trial of T\u2011Bren for HER2\u2011Mutant NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2110.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44030"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44030\/revisions"}],"predecessor-version":[{"id":44032,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44030\/revisions\/44032"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44031"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}